Antibodies to malondialdehyde-acetaldehyde modified low-density lipoprotein in patients with newly diagnosed inflammatory joint disease

2020 ◽  
pp. 1-5
Author(s):  
A Kononoff ◽  
S Hörkkö ◽  
P Pussinen ◽  
H Kautiainen ◽  
P Elfving ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Joint Disease ◽  
Low Density ◽  
Newly Diagnosed ◽  
Inflammatory Joint Disease

Low density lipoprotein of synovial fluid in inflammatory joint disease is mildly oxidized

Lipids ◽  
1998 ◽  
Vol 33 (11) ◽  
pp. 1115-1121 ◽  
Author(s):  
M. J. James ◽  
D. van Reyk ◽  
K. A. Rye ◽  
R. T. Dean ◽  
L. G. Cleland ◽  
...  
Keyword(s):  
Synovial Fluid ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Joint Disease ◽  
Low Density ◽  
Inflammatory Joint Disease

α-Tocopherol, lipids and lipoproteins in knee-joint synovial fluid and serum from patients with inflammatory joint disease

1992 ◽  
Vol 83 (6) ◽  
pp. 657-664 ◽  
Author(s):  
K. Fairburn ◽  
M. Grootveld ◽  
R. J. Ward ◽  
C. Abiuka ◽  
M. Kus ◽  
...  
Keyword(s):  
Synovial Fluid ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Serum Levels ◽  
Biologically Active ◽  
Joint Disease ◽  
Inflammatory Joint Disease ◽  
Serum Samples ◽  
Control Serum ◽  
Inflammatory Synovial Fluid

1. We have determined the antioxidant status of synovial fluid and serum of patients with inflammatory joint disease in terms of the biologically active lipid-soluble antioxidant, α-tocopherol. Synovial fluid concentrations of α-tocopherol were significantly lower relative to those of paired serum samples (P<0.001). Serum levels of α-tocopherol in these patients did not differ significantly from those in control serum. 2. Lower concentrations of cholesterol, triacylglycerol and low-density lipoprotein were also observed in patients' synovial fluid compared with matched serum samples. However, multiple regression analysis of the data indicated that there remained a significant depletion of α-tocopherol, which was largely independent of these co-variables, in inflammatory synovial fluid. These findings are consistent with the consumption of α-tocopherol within the inflamed joint via its role in terminating the process of lipid peroxidation. 3. Nuclear magnetic resonance spectroscopic analysis of matched inflammatory synovial fluid and serum confirmed lower concentrations of triacylglycerol in synovial fluid together with evidence of a shortened mean triacylglycerol chain length. The latter metabolic difference suggests an increased utilization of triacylglycerols for energy within the inflamed joint.

Effect of Antihypertensive Therapy on Serum Lipids in Newly Diagnosed Essential Hypertensive Men

Angiology ◽  
2008 ◽  
Vol 60 (2) ◽  
pp. 217-220 ◽  
Author(s):  
Hanumanthappa Nandeesha ◽  
Purushothaman Pavithran ◽  
T Madanmohan
Keyword(s):  
Serum Lipids ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Newly Diagnosed ◽  
Low Density Lipoprotein Cholesterol ◽  
Beneficial Effects ◽  
Lipid Status ◽  
Before And After

The effect of antihypertensives on serum lipids in newly diagnosed male essential hypertensive patients was studied. The participants (n = 99) were randomly allocated to receive amlodipine, atenolol, enalapril, hydrochlorothiazide, and a combination of amlodipine and atenolol. Lipid parameters were estimated before and after 8 weeks of therapy. The atenolol and thiazide group showed a significant increase in triglycerides (TGs) and very-low-density lipoprotein cholesterol (VLDL-C). High-density lipoprotein cholesterol (HDL-C) and HDL-C to low-density lipoprotein cholesterol (LDL-C) ratio were significantly increased and TC to HDL-C ratio was significantly decreased in the amlodipine and amlodipine–atenolol combination groups. In the enalapril group, we found a significant reduction in TC, TGs, VLDL-C, non-HDL-C, and TG to HDL-C ratio after treatment. It can be concluded from the present study that some drugs have beneficial effects on the lipid status, whereas others adversely affect the lipid status in hypertension.

Abstract 112: Low Plasma Low-density Lipoprotein Cholesterol Level as a Risk Factor for Cancer in Patients With Newly Diagnosed Coronary Artery Disease

2016 ◽  
Vol 36 (suppl_1) ◽  
Author(s):  
Xiaofeng Chen ◽  
Jianjun Jiang ◽  
Haihua Yang ◽  
Bing Wang ◽  
Yinsheng Xue ◽  
...  
Keyword(s):  
Risk Factors ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Stent Implantation ◽  
Low Density Lipoprotein ◽  
Cell Cancer ◽  
Density Lipoprotein ◽  
Low Density ◽  
Newly Diagnosed ◽  
Artery Disease

Background and Objective: Coronary artery disease (CAD) and cancer are the leading causes of death worldwide and share some risk factors, such as aging and smoking. Concurrence of CAD and cancers makes diagnosis and treatment more clinical challenging. In patients who need stent implantation followed by dual antiplatelet therapy, fatal perioperative complications such as bleeding and stent thrombosis may occur. There is no data regarding the prevalence and risk factors of cancer in patients with CAD. This study investigated the cancer prevalence and risk factors in patients with newly diagnosed CAD. Methods and Results: Three thousand and one hundred and eighty six consecutive patients with newly angiographically documented CAD were prospectively enrolled between January 2009 and March 2015. Serum levels of tumor markers, including carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen125, carbohydrate antigen 153, carbohydrate antigen199, squamous cell cancer antigen, and prostate-specific antigen, were measured. Diagnosis of cancer was confirmed by pathology or imaging with ultrasound, computed tomography or magnetic resonance. The prevalence of cancer in CAD patients was 1.1% (35 out of 3186), involving the in gastroenterogical, respiratory, endocrine and exocrine, urinary and hematopoietic systems. Among these cancer patients, 17 patients had stent implantation, with 7 AMI patients undergoing emergency PCI. Multivariate analysis revealed that, in addition to male gender and advanced age, lower plasma low-density lipoprotein (LDL) cholesterol levels were independently associated with the occurrence of cancer in CAD patients (P<0.01). Conclusion: Cancers occur in 1.1% of patients with CAD. Low LDL levels may increase the risk for cancers in the CAD patients. Further large scale studies are needed to validate this association.

Intralysosomal Accumulation of Colloidal Gold-Low Density Lipoprotein Conjugates in Chloroquine-Treated Fibroblasts

1985 ◽  
Vol 43 ◽  
pp. 546-547 ◽  
Author(s):  
Dean A. Handley ◽  
Cynthia M. Arbeeny ◽  
Larry D. Witte
Keyword(s):  
Colloidal Gold ◽  
Cultured Cells ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Coated Vesicle ◽  
Low Density ◽  
Cholesterol Esters ◽  
Cultured Fibroblasts ◽  
Surface Receptors ◽  
Ldl Particles

Low density lipoproteins (LDL) are the major cholesterol carrying particles in the blood. Using cultured cells, it has been shown that LDL particles interact with specific surface receptors and are internalized via a coated pit-coated vesicle pathway for lysosomal catabolism. This (Pathway has been visualized using LDL labeled to ferritin or colloidal gold. It is now recognized that certain lysomotropic agents, such as chloroquine, inhibit lysosomal enzymes that degrade protein and cholesterol esters. By interrupting cholesterol ester hydrolysis, chloroquine treatment results in lysosomal accumulation of cholesterol esters from internalized LDL. Using LDL conjugated to colloidal gold, we have examined the ultrastructural effects of chloroquine on lipoprotein uptake by normal cultured fibroblasts.

Sign in / Sign up

Export Citation Format

Share Document